Earlier this year, Regeneron scored a win when its eye drug Eylea outperformed a pair of Roche meds in a head-to-head study. And now, that win is paying off.
Hedge fund ValueAct revealed that it is the largest investor in British conglomerate the Smiths Group. It's expected to pursue a sale of that company's medical device business, Smiths Medical, as well as for its industrial process arm known as John Crane, according to a report from The Financial Times.
Drug sales crossed a significant metric last year. They grew past $1 trillion. And for those industry insiders thinking global sales will taper off, a new report says think again. Expect sales to top $1.3 trillion in 2018.
Hummelstown, PA-based startup MacuLogix has raised $5 million to back its FDA-cleared diagnostic test for dark adaptation function disorders, which include age-related macular degeneration and retinitis pigmentosa. The loss of the ability of the eye to adapt to the dark is a very early indicator of those kinds of diseases.
Olivier Brandicourt, CEO of Sanofi, gave his thoughts on the July 30 earnings call about trying to launch a simplification program in the midst of high-profile global rollouts, competition and dealmaking. He also picked one contest to watch in Japan that may be a good gauge of the company's performance on all counts.
Not so downbeat for Bayer Healthcare in China in the second quarter, though the consumer side like Johnson & Johnson is watching the mix of legacy and new sales channels and managing the integration of products picked up in the acquisition last quarter of Merck's consumer business.
GlaxoSmithKline joins other multinational pharma that witnessed a slowdown in China in the second quarter as heard on the July 29 earning call, with CEO Andrew Witty sounding in fine form, handling many of the questions directly.
For the second quarter, Pfizer gave the good news about continued strong Prevnar 13 sales in the U.S. But outside of a mention of possible approval in Japan in 2017, the company gave no update abroad and more importantly on China, where in April it halted vaccine operations following failure to get a license renewal for its existing Prevnar shot as Prevnar 13 also awaits approval.
Amgen rarely details much on international sales but did give a bit of background on Vectibix in Japan on the July 30 earnings call.
Amgen is only weeks away from an anticipated FDA approval for its PCSK9 cholesterol lowerer. Already approved in Europe, the drug is expected to quickly reap blockbuster sales. The biotech's current portfolio of products, along with cost cuts, have helped set the stage for a big year that could possibly include M&A.